REG - Solvonis Therapeutic - Appoints global biopharma leader Paul Carter

Solvonis TherapeuticsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nRSa8400Ea&default-theme=true

RNS Number : 8400E  Solvonis Therapeutics PLC  27 October 2025

27 October 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Appoints global biopharma leader Paul Carter as Non-Executive Director to
support next phase of strategic growth

 

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company
developing novel medicines for high-burden central nervous system ("CNS")
disorders, is delighted to announce the appointment of Paul Carter as
Non-Executive Director, effective 27 October 2025.

Paul Carter is a highly accomplished global biopharmaceutical leader with
nearly three decades of senior executive experience spanning commercial,
operational, and strategic leadership roles. He has built and scaled
businesses across Europe, North America, and Asia, combining deep operational
expertise with a proven record of driving transformational growth and
delivering long-term shareholder value.

Paul currently serves as Non-Executive Chair of Clinigen Group plc, a leading
global pharmaceutical services and supply company supporting access to
medicines in over 120 countries. He is also Chair of Memo Therapeutics AG, a
Swiss-based private clinical-stage biotech developing novel antibody
therapeutics, and Chair of Kyowa Kirin International plc, the European
subsidiary of Kyowa Kirin Co., Ltd. (TSE: 4151), a Japan-based global
specialty pharmaceutical company. In addition, Paul serves as Non-Executive
Director at Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical
company, pioneering TCR-based immunotherapies for cancer.

He previously held senior global roles including Executive Vice President and
Chief Commercial Officer at Gilead Sciences, Inc. (NASDAQ: GILD), where he
oversaw international operations across 38 markets and delivered annual
revenues exceeding US$30 billion.

His appointment strengthens the Solvonis Board as the Company continues to
advance its differentiated CNS pipeline and execute its capital-efficient,
licensing-first growth strategy across addiction, psychiatry, and neurology.

Anthony Tennyson, Chief Executive Officer of Solvonis, commented: "We are
delighted to welcome Paul to the Solvonis Board. He brings an exceptional
depth of global leadership experience and strategic insight from some of the
world's most successful pharmaceutical organisations. His expertise in scaling
innovative science into global commercial success will be invaluable as
Solvonis advances its CNS pipeline and builds towards the next phase of
sustainable growth."

Paul Carter added: "Solvonis is building an exciting and differentiated CNS
biopharmaceutical platform with significant potential to deliver impact for
patients and value for shareholders. I look forward to working with Anthony
and the Board to help shape strategy, strengthen partnerships, and support the
Company's continued evolution and growth."

 

Option Grant

Mr Carter has been granted 21 million share options under the Company's
existing long term incentive plan ("LTIP"), exercisable over ordinary shares
of £0.001 each in Solvonis Therapeutics Plc at an exercise price of £0.0034
per share. The options have a three-year life and vest in three equal
tranches: one-third on grant date, one-third on the first anniversary of grant
date, and one-third on the second anniversary of grant.

 

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Singer Capital Markets (Broker)

Phil Davies

+44 (0) 20 7496 3000

 

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company
developing novel small-molecule therapeutics for high-burden central nervous
system (CNS) disorders. Headquartered in London and listed on the main market
of the London Stock Exchange, Solvonis is advancing a differentiated pipeline
of repurposed and novel compounds across addiction, psychiatry, and neurology.

The Company's lead programmes address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD), with additional discovery work
supporting expansion into broader CNS indications. Its lead asset, SVN-001, is
currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for
a Phase 2b trial in the US targeting moderate-to-severe AUD. The preclinical
PTSD programme (SVN-SDN-14) leverages novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

In parallel, Solvonis is advancing proprietary CNS discovery programmes built
on a dedicated compound library to identify new small-molecule modulators of
key neurotransmitter systems. This platform enables efficient early-stage
innovation and supports the Company's integrated approach to developing
therapies across its three strategic pillars.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to deliver sustained value
through innovation in CNS therapeutics.

solvonis.com (https://solvonis.com) | LinkedIn
(https://www.linkedin.com/company/solvonis) | X (Twitter)
(https://x.com/Solvonis)

 

Director/PDMR MAR disclosures

The following notification, made in accordance with the requirements of the UK
Market Abuse Regulation, gives further details.

 

 1     Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                           Paul Carter
 2     Reason for the notification
 a)    Position/status                                                Non-Executive Director

 b)    Initial notification /Amendment                                Initial notification
 3     Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                           Solvonis Therapeutics Plc
 b)    LEI                                                            2138005PH7OJRCRPUD88
 4     Details of the transaction(s): section to be repeated for (i) each type of

     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the financial instrument, type of instrument    Ordinary shares of £0.001 each in Solvonis Therapeutics Plc

       Identification code

                                                                      Identification code (ISIN) for Solvonis Therapeutics Plc ordinary shares:
                                                                      GB00BMD1Z199
 b)    Nature of the transaction                                      Issue of Long Term Incentive Plan ('LTIPs')
 c)    Price(s) and volume(s)                                          Price(s)   Volume(s)
                                                                      £0.0034     21,000,000

 
 d)    Aggregated information:                                        N/A

       -      Aggregated volume

       -      Price
 e)    Date of the transaction                                        27 October 2025
 f)    Place of the transaction                                       London Stock Exchange, XLON

 

d)

Aggregated information:

-      Aggregated volume

-      Price

N/A

e)

Date of the transaction

27 October 2025

f)

Place of the transaction

London Stock Exchange, XLON

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAVQLFLEBLBFBV



            Copyright 2019 Regulatory News Service, all rights reserved